Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer.

Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S.

Oncogene. 2013 Mar 28;32(13):1616-25. doi: 10.1038/onc.2012.193. Epub 2012 May 21.

2.

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF.

J Clin Oncol. 2011 Nov 10;29(32):4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11.

PMID:
21990413
4.

Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis.

Ren J, Li G, Ge J, Li X, Zhao Y.

Dis Colon Rectum. 2012 Aug;55(8):913-23. doi: 10.1097/DCR.0b013e318251d8d9. Review.

PMID:
22810479
5.

Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis.

Anami Y, Iijima T, Suzuki K, Yokota J, Minami Y, Kobayashi H, Satomi K, Nakazato Y, Okada M, Noguchi M.

J Thorac Oncol. 2009 Aug;4(8):951-8. doi: 10.1097/JTO.0b013e3181ad8631.

6.

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z.

Cancer Discov. 2012 Jul;2(7):638-51. doi: 10.1158/2159-8290.CD-12-0093. Epub 2012 May 10.

7.

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL.

Cell. 2009 Jul 23;138(2):286-99. doi: 10.1016/j.cell.2009.05.045.

8.

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.

Custodio A, Feliu J.

Crit Rev Oncol Hematol. 2013 Jan;85(1):45-81. doi: 10.1016/j.critrevonc.2012.05.001. Epub 2012 May 28. Review.

PMID:
22647972
9.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
10.

As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling.

Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, Chen ZY, Xiang YQ, Bao YN, Zheng FJ, Zeng MS, Kang TB, Zeng YX, Teh BT, Qian CN.

Carcinogenesis. 2012 Jul;33(7):1302-9. doi: 10.1093/carcin/bgs181. Epub 2012 May 18.

11.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA.

Cancer. 2012 Aug 15;118(16):4014-23. doi: 10.1002/cncr.26724. Epub 2011 Dec 16.

12.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK.

J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.

PMID:
19826129
13.

Radial nerve palsy associated with humeral shaft fracture. Is the energy of trauma a prognostic factor?

Venouziou AI, Dailiana ZH, Varitimidis SE, Hantes ME, Gougoulias NE, Malizos KN.

Injury. 2011 Nov;42(11):1289-93. doi: 10.1016/j.injury.2011.01.020. Epub 2011 Feb 24.

PMID:
21353219
14.

CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS.

Cancer Res. 2013 Jan 15;73(2):571-82. doi: 10.1158/0008-5472.CAN-12-0263. Epub 2012 Nov 30.

15.

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.

Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, Schouwink JH, Wijnands WJ, Kerner GS, Kruyt FA, Tissing H, Tibbe AG, Terstappen LW, Groen HJ.

Ann Oncol. 2012 Nov;23(11):2937-42. doi: 10.1093/annonc/mds138. Epub 2012 Jun 11.

PMID:
22689177
16.

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.

Liersch R, Gerss J, Schliemann C, Bayer M, Schwöppe C, Biermann C, Appelmann I, Kessler T, Löwenberg B, Büchner T, Hiddemann W, Müller-Tidow C, Berdel WE, Mesters R.

Blood. 2012 May 31;119(22):5215-20. doi: 10.1182/blood-2011-11-389692. Epub 2012 Apr 17.

17.

MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.

Jarboe JS, Anderson JC, Duarte CW, Mehta T, Nowsheen S, Hicks PH, Whitley AC, Rohrbach TD, McCubrey RO, Chiu S, Burleson TM, Bonner JA, Gillespie GY, Yang ES, Willey CD.

Clin Cancer Res. 2012 Jun 1;18(11):3030-41. doi: 10.1158/1078-0432.CCR-11-3091. Epub 2012 May 22.

18.

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.

Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA.

Leuk Lymphoma. 2008 Sep;49(9):1745-51. doi: 10.1080/10428190802226425.

PMID:
18798109
19.

Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH.

Oncogene. 2010 Feb 25;29(8):1093-102. doi: 10.1038/onc.2009.416. Epub 2009 Nov 30. Review.

PMID:
19946335
20.

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ.

J Clin Oncol. 2005 Sep 1;23(25):5900-9. Epub 2005 Jul 25.

PMID:
16043828

Supplemental Content

Support Center